[go: up one dir, main page]

AR104984A1 - Compuestos selectivos para pyy y sus usos - Google Patents

Compuestos selectivos para pyy y sus usos

Info

Publication number
AR104984A1
AR104984A1 ARP160101755A ARP160101755A AR104984A1 AR 104984 A1 AR104984 A1 AR 104984A1 AR P160101755 A ARP160101755 A AR P160101755A AR P160101755 A ARP160101755 A AR P160101755A AR 104984 A1 AR104984 A1 AR 104984A1
Authority
AR
Argentina
Prior art keywords
pyy
compounds
application
selective compounds
refers
Prior art date
Application number
ARP160101755A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR104984A1 publication Critical patent/AR104984A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)

Abstract

La solicitud hace referencia a compuestos para PYY con las modificaciones de aminoácidos 7Lys, 30Trp y 31Leu y además 22Ile o 28Tyr, y sus derivados. El compuesto de la solicitud corresponde a agonistas del receptor Y2 selectivo. La solicitud también hace referencia a composiciones farmacéuticas que comprenden dichos compuestos para PYY y excipientes farmacéuticamente aceptables, como también al uso médico de los compuestos para PYY.
ARP160101755A 2015-06-12 2016-06-13 Compuestos selectivos para pyy y sus usos AR104984A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15171785 2015-06-12

Publications (1)

Publication Number Publication Date
AR104984A1 true AR104984A1 (es) 2017-08-30

Family

ID=53404384

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101755A AR104984A1 (es) 2015-06-12 2016-06-13 Compuestos selectivos para pyy y sus usos

Country Status (19)

Country Link
US (1) US10005824B2 (es)
EP (1) EP3307768B1 (es)
JP (1) JP6731958B2 (es)
KR (1) KR102476550B1 (es)
CN (1) CN107849110B (es)
AR (1) AR104984A1 (es)
AU (1) AU2016275735B2 (es)
BR (1) BR112017025108A2 (es)
CA (1) CA2988500A1 (es)
ES (1) ES3019234T3 (es)
IL (1) IL255781B (es)
MA (1) MA43205A (es)
MX (1) MX392572B (es)
MY (1) MY187047A (es)
RU (1) RU2726777C2 (es)
SA (1) SA517390445B1 (es)
TW (1) TWI694082B (es)
WO (1) WO2016198682A1 (es)
ZA (1) ZA201707782B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60321B1 (sr) 2010-12-16 2020-07-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline
LT2827885T (lt) 2012-03-22 2018-10-10 Novo Nordisk A/S Glp-1 peptidų kompozicijos ir jų gavimas
RU2671406C2 (ru) 2013-05-02 2018-10-31 Ново Нордиск А/С Пероральная дозированная форма соединений глюкагоноподобного пептида-1
EP3068795B1 (en) 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
AU2014350197B2 (en) 2013-11-15 2018-10-04 Novo Nordisk A/S Selective PYY compounds and uses thereof
WO2017218072A1 (en) 2016-06-14 2017-12-21 Purecircle Usa Inc. Steviol glycosides compositions, production methods and uses
HUE063787T2 (hu) 2018-02-02 2024-01-28 Novo Nordisk As Egy GLP-1 agonistát, egy N-(8-(2-hidroxibenzoil)amino) kaprilsav sót és egy síkosítóanyagot tartalmazó szilárd készítmények
TWI749381B (zh) 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
ES2969534T3 (es) * 2019-08-07 2024-05-21 Novo Nordisk As Composición sólida que comprende un compuesto del PYY y una sal de ácido N-(8-(2-hidroxibenzoil)amino)caprílico
JOP20220110A1 (ar) * 2019-11-11 2023-01-30 Boehringer Ingelheim Int ناهضات مستقبل npy2
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
MX2023001532A (es) 2020-08-07 2023-03-08 Boehringer Ingelheim Int Agonistas del receptor npy2 solubles.
JP2023551122A (ja) * 2020-11-09 2023-12-07 エンバーク バイオテック エーピーエス 化合物およびタキキニン受容体介在性障害の治療におけるその使用
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
EP4259647A4 (en) 2021-09-15 2025-03-26 Viking Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
US20250000948A1 (en) 2021-11-15 2025-01-02 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
CN115960258B (zh) * 2022-09-30 2024-01-12 广西医科大学附属肿瘤医院 一类GLP-1/glucagon/Y2受体三重激动剂及其应用
WO2025128626A1 (en) * 2023-12-12 2025-06-19 Carmot Therapeutics, Inc. Hybrid peptide compounds having a modified lysine residue

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960701653A (ko) * 1993-03-29 1996-03-28 발라수브라마니암 엠비카이파칸 펩타이드 yy의 유사체 및 그의 용도
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
JP2000505105A (ja) 1996-11-13 2000-04-25 ユニヴァーシティ・オブ・シンシナティ ペプチドｙｙのアナログおよびその使用
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
IL139913A0 (en) 1998-06-08 2002-02-10 Schering Corp Neuropeptide y5 receptor antagonists
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
WO2002047712A2 (en) * 2000-12-14 2002-06-20 Amylin Pharmaceuticals, Inc. Peptide yy and peptide yy agonists for treatment of metabolic disorders
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
ES2320979T3 (es) 2001-09-24 2009-06-01 Imperial Innovations Limited Pyy-36 para la reduccion o prevencion de la obesidad.
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
WO2004066966A2 (en) 2003-01-17 2004-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide yy analogs
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
US20070203058A1 (en) 2003-09-19 2007-08-30 Novo Nordisk A/S Novel Glp-1 Derivatives
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
EP1696962A2 (en) 2003-12-18 2006-09-06 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
US8603969B2 (en) 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
BRPI0508935A (pt) 2004-03-17 2007-09-25 7Tm Pharmas As agonistas de receptor seletivo y4 para intervenções terapêuticas
GB2427550B (en) 2004-03-17 2007-05-30 7Tm Pharma As Y2/Y4 selective receptor agonists for therapeutic interventions
EA011860B1 (ru) 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецептора y2 для терапевтического воздействия
CN1933848A (zh) 2004-03-17 2007-03-21 7Tm制药联合股份有限公司 用于治疗性干预的y2选择性受体激动剂
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
JP2008507477A (ja) 2004-07-08 2008-03-13 ノボ　ノルディスク　アクティーゼルスカブ ポリペプチド延長タグ
WO2006020207A2 (en) 2004-07-19 2006-02-23 University Of Cincinnati Compounds for control of appetite
NZ553149A (en) 2004-08-12 2010-01-29 Quest Pharmaceutical Services Use of inositol hexaphosphate or inositol hexasulphate to complex biologically active compounds for the preparation of controlled release pharmaceutical compositions
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
JP2009500453A (ja) 2005-07-11 2009-01-08 ナステック ファーマスーティカル カンパニー インク． 向上されたｐｙｙの粘膜送達用製剤
CN101222942A (zh) 2005-07-18 2008-07-16 诺沃-诺迪斯克有限公司 用于治疗肥胖的肽
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
CA2623088A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
AU2005337101A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
NZ568772A (en) 2005-12-07 2010-05-28 Hoffmann La Roche Truncated analogs of the peptide pYY3-36 that are neuropeptide-2 receptor-agonists
JP2009519296A (ja) 2005-12-14 2009-05-14 ノボ・ノルデイスク・エー／エス ポリペプチド延長タグ
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
CN101432025B (zh) 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2008008363A1 (en) 2006-07-11 2008-01-17 Qps, Llc Pharmaceutical compositions for sustained release delivery of peptides
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
JP2010516652A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
WO2008087190A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
AU2008273941B2 (en) 2007-07-09 2014-01-16 Imperial Innovations Limited Human pancreatic polypeptide (HPP) analogues and their effects on feeding behaviour
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
EP2187935A2 (en) * 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent
WO2009042922A2 (en) 2007-09-27 2009-04-02 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
MX2010011845A (es) * 2008-05-16 2010-11-22 Novo Nordisk As Agonistas del receptor y2 y/o y4 de larga accion.
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
JP2012507487A (ja) 2008-11-05 2012-03-29 エフ．ホフマン−ラ ロシュ アーゲー 神経ペプチド２受容体（ｙ−２ｒ）アゴニスト及びその使用
JP5584236B2 (ja) 2009-02-20 2014-09-03 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ 神経ペプチドｙ受容体結合化合物を有する細胞毒性コンジュゲート
EP2477643A1 (en) * 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
CA2776302A1 (en) 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
US20130096055A1 (en) 2009-11-13 2013-04-18 Novo Nordisk A/S Long-acting y2 receptor agonists
EP2560675A1 (en) 2010-04-20 2013-02-27 Novo Nordisk A/S Long-acting gastrin derivatives
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
EP2855517A1 (en) 2012-05-29 2015-04-08 Novo Nordisk A/S Pancreatic polypeptide compounds and use
RU2015144632A (ru) 2013-05-02 2017-06-07 Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Терапевтические пептиды
AU2014350197B2 (en) * 2013-11-15 2018-10-04 Novo Nordisk A/S Selective PYY compounds and uses thereof
EP3068795B1 (en) * 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35

Also Published As

Publication number Publication date
EP3307768C0 (en) 2025-01-29
US10005824B2 (en) 2018-06-26
AU2016275735B2 (en) 2020-02-06
US20170313750A1 (en) 2017-11-02
RU2726777C2 (ru) 2020-07-15
SA517390445B1 (ar) 2020-12-21
MA43205A (fr) 2018-09-19
IL255781A (en) 2018-04-30
EP3307768B1 (en) 2025-01-29
WO2016198682A1 (en) 2016-12-15
RU2017145348A3 (es) 2019-09-09
CN107849110A (zh) 2018-03-27
MX2017015105A (es) 2018-05-07
JP2018522843A (ja) 2018-08-16
BR112017025108A2 (pt) 2018-07-31
TW201710284A (zh) 2017-03-16
CN107849110B (zh) 2021-11-26
EP3307768A1 (en) 2018-04-18
JP6731958B2 (ja) 2020-07-29
TWI694082B (zh) 2020-05-21
ZA201707782B (en) 2019-08-28
MY187047A (en) 2021-08-27
RU2017145348A (ru) 2019-07-12
IL255781B (en) 2021-10-31
ES3019234T3 (en) 2025-05-20
MX392572B (es) 2025-03-24
CA2988500A1 (en) 2016-12-15
AU2016275735A1 (en) 2017-12-07
KR102476550B1 (ko) 2022-12-13
KR20180019616A (ko) 2018-02-26

Similar Documents

Publication Publication Date Title
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
BR112016010383A2 (pt) compostos de pyy seletivos e usos dos mesmos
CL2018003681A1 (es) Derivados de ácido borónico y usos terapéuticos de los mismos
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
UY39706A (es) Derivados de (1hindol- 3-il)-2-(4-cloro-2-metoxi-fenil)-2-((3-metoxi-5-(metilsulfonil) fenil)amino)etanona como inhibidores de la replicación del virus del dengue
MX2018001721A (es) 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer.
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX393586B (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
MX2018011785A (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue.
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2018004295A (es) Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar.
MX384392B (es) Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales.
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
AR096338A1 (es) (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles
UY36124A (es) Derivados de carboxamida
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.

Legal Events

Date Code Title Description
FB Suspension of granting procedure